Cargando…

Treatment of Women with Multiple Sclerosis Planning Pregnancy

PURPOSE OF REVIEW: We review data available for treatment of multiple sclerosis (MS) before, during, and after pregnancy. We present recent data on disease-modifying therapies (DMT) before/during pregnancy and while breastfeeding, with treatment recommendations. RECENT FINDINGS: Observational data s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krysko, Kristen M., Bove, Riley, Dobson, Ruth, Jokubaitis, Vilija, Hellwig, Kerstin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Multiple Sclerosis and Related Disorders (J Graves, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008016/ https://www.ncbi.nlm.nih.gov/pubmed/33814892 http://dx.doi.org/10.1007/s11940-021-00666-4

Ejemplares similares

Early Aggressive Treatment Approaches for Multiple Sclerosis
por: Simpson, Alexandra, et al.
Publicado: (2021)

New Therapeutic Landscape in Neuromyelitis Optica
por: Tugizova, Madina, et al.
Publicado: (2021)

Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses
por: Novak, Frederik, et al.
Publicado: (2023)

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme
por: Palace, Jacqueline, et al.
Publicado: (2019)

Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
por: Cerqueira, João J, et al.
Publicado: (2018)

The contribution of neuropathology to multiple sclerosis research
por: Lassmann, Hans
Publicado: (2022)

Pregnancy outcomes after early fetal exposure to injectable first‐line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis
por: Andersen, Johanna Balslev, et al.
Publicado: (2022)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis
por: Manjaly, Zina-Mary, et al.
Publicado: (2019)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Stressful life events are associated with the risk of multiple sclerosis
por: Jiang, X., et al.
Publicado: (2020)

Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

Structural network disruption markers explain disability in multiple sclerosis
por: Charalambous, Thalis, et al.
Publicado: (2019)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
por: Nij Bijvank, Jenny, et al.
Publicado: (2022)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Brain age as a surrogate marker for cognitive performance in multiple sclerosis
por: Denissen, Stijn, et al.
Publicado: (2022)

Smartphone‐derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis
por: Lam, Ka‐Hoo, et al.
Publicado: (2021)

Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis
por: Magyari, Melinda, et al.
Publicado: (2022)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

Automated brain volumetrics in multiple sclerosis: a step closer to clinical application
por: Wang, C, et al.
Publicado: (2016)

A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
por: Nij Bijvank, Jenny A., et al.
Publicado: (2021)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

First‐line therapies in late‐onset multiple sclerosis: An Italian registry study
por: Zanghì, Aurora, et al.
Publicado: (2021)

Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression
por: Wu, Jing, et al.
Publicado: (2023)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f52h8a19f5cfu05jo4kr80rclk